iTeos Therapeutics to Present at Wedbush PacGrow Healthcare Conference 2021
August 03 2021 - 7:00AM
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage
biopharmaceutical company pioneering the discovery and development
of a new generation of highly differentiated immuno-oncology
therapeutics for patients, today announced that Michel Detheux,
PhD, President and Chief Executive Officer, will present at the
upcoming Wedbush PacGrow Healthcare Conference 2021 on Tuesday,
August 10, 2021 at 2:20 p.m. ET.
A live webcast of the presentation will be available on the
Investors section of the company’s website at
https://www.iteostherapeutics.com. An archived replay will be
available for approximately 30 days following the presentation.
About iTeos Therapeutics, Inc.iTeos
Therapeutics is a clinical-stage biopharmaceutical company
pioneering the discovery and development of a new generation of
highly differentiated immuno-oncology therapeutics for patients.
The Company’s innovative pipeline includes two clinical-stage
programs targeting novel, validated immuno-oncology. The initial
antibody product candidate, EOS-448, is a high affinity, potent,
anti-TIGIT antibody with a functional Fc domain, designed to
enhance the anti-tumor response through a multifaceted immune
modulatory mechanism. An open-label Phase 1 clinical trial of
EOS-448 is ongoing in adult cancer patients with advanced solid
tumors with preliminary data indicating preliminary clinical
activity as a monotherapy and a favorable tolerability profile. The
Company is also advancing inupadenant, a first insurmountable
adenosine A2A receptor antagonist in clinical development tailored
to overcome cancer immunosuppression. iTeos is conducting an
open-label multi-arm Phase 1/2a clinical trial of inupadenant in
adult cancer patients with advanced solid tumors. Preliminary
results indicate encouraging single-agent activity as well as the
identification of a potential predictive biomarker. iTeos
Therapeutics is headquartered in Cambridge, MA with a research
center in Gosselies, Belgium.
For further information, please contact:
Investor Contact:Ryan BakeriTeos Therapeutics,
Inc.Ryan.Baker@iteostherapeutics.com
Media Contact: media@iteostherapeutics.com
iTeos Therapeutics (NASDAQ:ITOS)
Historical Stock Chart
From Aug 2024 to Sep 2024
iTeos Therapeutics (NASDAQ:ITOS)
Historical Stock Chart
From Sep 2023 to Sep 2024